Non-Invasive Tear Biomarkers of T2DM
Non-Invasive Tear Biomarkers of T2DM
To develop a non-invasive test for early screening and monitoring of type 2 diabetes mellitus
Currently, invasive blood test is a common way to perform screening for type 2 diabetes mellitus (T2DM). The venture aims to develop and introduce a non-invasive test for early screening and monitoring of T2DM using protein biomarkers obtained from tear fluid. This alternative method can eliminate the fear, pain and wound caused by finger-pricking necessary for blood tests. Early screening and monitoring enable patients to receive timely treatment and a better prognosis, resulting in reduced potential medical expenses. The goal of the team is to turn laboratory innovations into clinical applications to foster the advancement of the healthcare industry.
Name of Organisation
(Not applicable)
Approved Funding Amount
HK$100,000
Funding Period (Status)
24 months (Ended)
Impact/Outcomes
- Developed a non-invasive test for early screening of T2DM by using protein biomarkers obtained from tear fluid
- A total of 37 participants aged 50 or above received optometric services for early screening of T2DM
Website
(To be updated when available)